DEF 14A: 23andMe Seeks Stockholder Approval for Reverse Stock Split Amidst Nasdaq Compliance Efforts

23andMe is asking stockholders to approve a reverse stock split to boost its share price and maintain its Nasdaq listing.

Summary

• 23andMe is holding its 2024 Annual Meeting of Stockholders on August 26, 2024, virtually.
• Stockholders of record as of June 27, 2024, are entitled to vote.
• The company is seeking approval for several proposals, including the election of directors, an advisory vote on executive compensation, a reverse stock split, and ratification of the independent auditor.
• A key proposal is an amendment to the Certificate of Incorporation to allow for a reverse stock split of Class A and Class B common stock at a ratio between 1-for-5 and 1-for-30, with the exact ratio determined by the Board.
• The reverse stock split aims to increase the company's stock price to meet Nasdaq's minimum bid price requirement of $1.00 per share.
• The Board believes a higher stock price will improve the stock's acceptability to institutional investors and the investing public.
• The Board has the discretion to abandon the reverse stock split if it's no longer in the company's best interest.
• The company is exploring various financing options, including potential future sales of Class A common stock or other securities.
• If the reverse stock split is approved, adjustments will be made to outstanding stock options and restricted stock units.
• The company's mission is to help people access, understand, and benefit from the human genome.
• 23andMe has over 15 million genotyped customers and is focused on health risk prediction and therapeutic drug development.
• The company has research and development programs across several therapeutic areas, including oncology, immunological, and inflammatory diseases.
• As of March 31, 2024, two internal programs have entered clinical trials.
• The company is committed to corporate social responsibility and diversity, equity, and inclusion (DE&I).
• In Fiscal 2024, 50% of new hires self-identified as ethnically or racially diverse.
• The Board recommends voting FOR all director nominees, the say-on-pay proposal, the reverse stock split, and the ratification of KPMG LLP.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive aspects such as progress in therapeutic development and commitment to DE&I, the need for a reverse stock split and the Adjusted EBITDA results indicate financial challenges.

Positives

• The company is actively working to maintain its Nasdaq listing through the proposed reverse stock split.
• 23andMe is making progress in therapeutic drug development, with two programs in clinical trials.
• The company is committed to DE&I, with a significant percentage of new hires identifying as ethnically or racially diverse.
• The company has a valuable database of genetic and phenotypic information, as evidenced by the data license agreement with GSK.
• The company is expanding its health services, including the launch of Total Health and new genetic reports.
• The company is partnering with organizations like StreetCode Academy and Kode with Klossy to support community engagement and tech education.

Negatives

• The company's Class A common stock has been trading below $1.00 per share, leading to a Nasdaq non-compliance notice.
• The company's Adjusted EBITDA for Fiscal 2024 was $(176 million), which did not meet the threshold for annual incentive plan payouts.
• The company experienced a cybersecurity incident in October 2023, which required implementing additional security measures.
• The company's genetic database is Eurocentric, which has historically limited the value of its products for individuals with non-European backgrounds.

Risks

• Failure to maintain the minimum bid price on Nasdaq could lead to delisting, resulting in decreased liquidity and investor interest.
• The reverse stock split may not increase the stock price or improve the company's financial position.
• The company may not be able to successfully raise sufficient additional capital, which could impact its ability to fund operations.
• The company faces risks related to cybersecurity and data privacy, as highlighted by the October 2023 incident.
• The company's reliance on a Eurocentric genetic database could limit its ability to serve diverse populations effectively.

Future Outlook

The company aims to continue growth by leveraging its unique genetic data and tools, enhancing genetic understanding, optimizing health outcomes, and bringing new therapeutics to patients. They are exploring various financing options, including potential future sales of Class A common stock or other securities.

Management Comments

• Anne Wojcicki, CEO, stated that the company continued to make progress in its mission to help people access, understand, and benefit from the human genome during Fiscal 2024.
• Management believes that the company has a unique set of genetic data and tools that will continue growth well into the future.

Industry Context

The announcement relates to broader industry trends in personalized healthcare, direct-to-consumer genetic testing, and drug discovery. Competitors in the genetic testing space include AncestryDNA and MyHeritage DNA. In the pharmaceutical space, 23andMe partners with and competes with companies like GSK and Novartis.

Comparison to Industry Standards

• The document mentions a peer group of companies used for executive compensation benchmarking, including 10x Genomics, Inc., Denali Therapeutics Inc., and Natera, Inc.
• The company's commitment to DE&I is compared to industry standards through participation in the Disability Equality Index and the Fair360 Top 50 Survey.
• The company's data security practices are benchmarked against ISO/IEC 27001:2013, ISO/IEC 27701:2019, and ISO/IEC 27018:2019 standards.

Related Party Transactions

• The company recognized revenue of $11.8 million under the GSK Agreements.
• The company paid Dr. Richard Scheller $120,000 pursuant to the Consulting Agreement.

Stakeholder Impact

• Shareholders: The reverse stock split could impact the stock price and liquidity.
• Employees: The company's financial performance and potential capital raise could affect job security and compensation.
• Customers: The company's ability to invest in research and development could impact the quality and availability of its products and services.
• Partners: The company's financial stability could impact its ability to fulfill its obligations under collaboration agreements.

Next Steps

• Stockholder vote on the proposals at the Annual Meeting on August 26, 2024.
• Board decision on whether to implement the reverse stock split and the specific ratio within 90 days after the Annual Meeting.
• Filing of the Certificate of Amendment with the Secretary of State of Delaware if the reverse stock split is approved.
• Continued efforts to regain compliance with Nasdaq's minimum bid price requirement.
• Exploration of various financing options to secure additional capital.

Key Dates

Keywords

reverse stock split, proxy statement, annual meeting, Nasdaq, executive compensation, directors, 23andMe, genetics, therapeutics, DE&I